3,4-Dihydroxy-L-phenylalanine (L-DOPA)
CAT:
952-B2014887
Size:
1 g
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


3,4-Dihydroxy-L-phenylalanine (L-DOPA)
Description:
3,4-Dihydroxy-L-phenylalanine (L-DOPA)_x000D_ Catalog number: B2014887_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 1 g_x000D_ Molecular Weight or Concentration: 197.19 g/mol_x000D_ Supplied as: Powder_x000D_ Applications: molecular tool for various biochemical applications_x000D_ Storage: RT_x000D_ Keywords: 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease Mov Disord. 2010 Nov 15;25(15):2649-53._x000D_ 2: Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease Mov Disord. 2008;23 Suppl 3:S497-508._x000D_ 3: Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease Molecules. 2017 Dec 25;23(1):40._x000D_ 4: Levodopa Nurs Times. 2005 Nov 22-28;101(47):27._x000D_ 5: Ayyadurai N, Prabhu NS, Deepankumar K, Jang YJ, Chitrapriya N, Song E, Lee N, Kim SK, Kim BG, Soundrarajan N, Lee S, Cha HJ, Budisa N, Yun H. Bioconjugation of L-3,4-dihydroxyphenylalanine containing protein with a polysaccharide Bioconjug Chem. 2011 Apr 20;22(4):551-5._x000D_ 6: Ihara M, Tsuchiya Y, Sawasaki Y, Hisaka A, Takehana H, Tomimoto K, Yano M. A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine J Pharm Sci. 1989 Jul;78(7):525-9._x000D_ 7: Levodopa for parkinsonism Br Med J. 1971 Jan 30;1(5743):244-5._x000D_ 8: Shpiner DS, Bette S, Di Luca DG, Margolesky J. CVT-301 for the treatment of Parkinson's disease Expert Rev Neurother. 2019 Jul;19(7):603-611._x000D_ 9: Abbruzzese G. Optimising levodopa therapy Neurol Sci. 2008 Dec;29 Suppl 5:S377-9._x000D_ 10: Creasey HM, Broe GA. Parkinson's disease Med J Aust. 1993 Aug 16;159(4):249-53. _x000D_ _x000D_ Products Related to 3,4-Dihydroxy-L-phenylalanine (L-DOPA) can be found at ChemicalsShort Description:
Catalog Number: B2014887 (1 g)Weight:
0.8Length:
2Width:
0.9Height:
0.9Height :
0.9